Talphera (TLPH) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing innovative therapies for medically supervised settings, including Niyad (regional anticoagulant for dialysis), LTX-608 (nafamostat for IV infusion), and two pre-filled syringe product candidates (Fedsyra and phenylephrine).

• Strategy centers on developing, obtaining approval for, and commercializing Niyad, with plans to expand into additional acute care therapies.

• Incorporated in Delaware, with principal offices in San Mateo, CA; previously known as SuRx, Inc. and AcelRx Pharmaceuticals, Inc.

Financial performance and metrics

• Raised approximately $1.6 million in gross proceeds from a private placement of common stock and pre-funded warrants in March and October 2025.

• As of October 25, 2025, had 46,609,618 shares of common stock issued and outstanding.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders; all proceeds go to the selling stockholders.